
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is a financially strong company with a solid track record of revenue growth, margin improvement, shareholder returns and smart capital allocation. Despite facing challenges in some markets, the company's strong earnings in FY2026 and planned launch of new products indicate a positive outlook for continued growth. With a majority of revenue coming from the United States and a focus on increasing shareholder returns, BD is well-positioned for future success.
Bears say
Becton Dickinson is facing headwinds in its Medical, Life Sciences, and Interventional segments, with weaker revenue growth and lower market demand for its products. Additionally, ongoing challenges in China, funding cuts, tariffs, and changing healthcare delivery and reimbursement could negatively impact the company's sales and operations. These risks, coupled with competition from larger and more specialized firms, could hinder BD's ability to achieve its financial targets and create a downside scenario for the stock.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares